311 results
Page 7 of 16
8-K
EX-99.1
yrhy1 h98w
19 Oct 12
A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer
12:00am
8-K
EX-99.1
c4mvpdwlxdy
17 Oct 12
A.P. Pharma Announces PDUFA Action Date
12:00am
8-K
EX-99.1
nu4 9iyebpn68lg3a
1 Oct 12
A.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting
12:00am
8-K
EX-99.1
auvhxza
10 Sep 12
A.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President of Business Development
12:00am
424B3
hoocmi mqj
9 Aug 12
Prospectus supplement
12:00am
424B3
14nw51
9 Aug 12
Prospectus supplement
12:00am
8-K
EX-99.1
uqb0e9
2 Aug 12
A.P. Pharma Announces Second Quarter 2012 Financial Results and Highlights Recent Corporate Progress
12:00am
8-K
EX-99.1
5kw67fn2y6
31 Jul 12
A.P. Pharma Appoints Robert Rosen to Its Board of Directors
12:00am
8-K
EX-10.1
s9lwz8
25 Jul 12
A.P. Pharma to Raise $53.6 Million in Common Stock Offering
12:00am
8-K
EX-99.1
yqhsdsncivv4xfycc
25 Jul 12
A.P. Pharma to Raise $53.6 Million in Common Stock Offering
12:00am
8-K
EX-99.2
4y6w32 0j
25 Jul 12
A.P. Pharma to Raise $53.6 Million in Common Stock Offering
12:00am
8-K
EX-99.1
vljpqi
12 Jul 12
A.P. Pharma Announces the Allowance of
12:00am
8-K
EX-99.1
8fteywmc hi
3 Jul 12
A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and Vomiting
12:00am
8-K
EX-99.1
4ecv59bmzczeeun
22 Jun 12
A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study
12:00am
8-K
ln6keydft8u7vwq91 f8
22 Jun 12
A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study
12:00am
424B3
zw655i hjpny7ohvcgr
3 Apr 12
Prospectus supplement
12:00am
424B3
0laa e0w0hd
3 Apr 12
Prospectus supplement
12:00am